Verastem, Inc.
VSTMHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Verastem, Inc. focuses on Biotechnology services and products. Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. With a market capitalization of $529.9M, it sits in small-cap territory. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Market Cap
$529.9M
Beta
0.29
P/E (TTM)
—
P/E (Fwd)
-5.20
EPS (TTM)
$-2.52
EPS (Fwd)
$-1.16
ROE
-786.2%
ROA
-59.4%
Cash
$181.7M
Total Debt
$85.5M
Free CF
-$92.7M
52W Change
16.9%
Annual Financials
Cash vs Debt
Verastem, Inc. holds $181.7M in cash against $85.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$92.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -786.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.6M (2022) to $30.9M (2025), reflecting a 1091% increase over the period.
The relatively low beta of 0.29 suggests VSTM is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, VSTM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VSTM.